It is very exciting to be a urologist today, seeing how biomarkers are proving to be invaluable tools in the diagnosis, prognosis and treatment of prostate cancer.
Location
Detroit, Michigan, USA
By the numbers
29 years of experience in urology
52 clinical trials led
69 peer-reviewed publications focused on prostate cancer
It is very exciting to be a urologist today, seeing how biomarkers are proving to be invaluable tools in the diagnosis, prognosis and treatment of prostate cancer.
About Dr Jason Hafron
Dr Jason Hafron is the Chief Medical Officer and Medical Director of Clinical Research at the Michigan Institute of Urology. He is also a Professor of Urology at the William Beaumont School of Medicine, Oakland University in Royal Oak. He is experienced in all areas of adult urology, with a specialization in the minimally invasive treatment of cancers involving the prostate, kidney and bladder using laparoscopic and robotic surgery.
Dr Hafron has published extensively in peer-reviewed journals and presents regularly at many national and international scientific meetings. He is the principal investigator for multiple clinical research trials at the Michigan Institute of Urology, and is the recipient of many clinical research awards.
He serves on the editorial board of International Urology and Nephrology, Urology Times and Urologists in Cancer Care. Additionally, he previously served on the board of directors of the United Physicians Organization and currently serves on the board of directors for the Large Group Practice Association. He has been repeatedly named “Top Doctor” by Hour Detroit Magazine and by Castle Connolly.
Key areas of interest
- Development of prostate cancer care pathways to enhance patient outcomes
- Application of data analytics to optimize care delivery and improve patient experience
- Integration of biomarkers for tailoring treatment to individual patient profiles
Dr Jason Hafron has been compensated by AstraZeneca for their time and expertise in contributing to this initiative.
Explore key pages
AKT, protein kinase B; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
